GLP1R and type 2 diabetes mellitus: Its use should be restricted to male patients with T2DM who also present with symptomatic hypogonadism, aiming primarily to improve metabolic parameters and potentially enhance the effectiveness of other core remission therapies, such as lifestyle interventions or GLP-1 receptor agonists.